Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs DexCom, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while DexCom, Inc. trades at $90.64 (market cap $33.79B). The key difference: Alnylam Pharmaceuticals, Inc. and DexCom, Inc. are close in size by market cap, and DexCom, Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DXCM | |
|---|---|---|
Market Cap | $29.60B | $33.79B |
Sector | Health | Health |
52-Week High | $491.22 | $89.53 |
52-Week Low | $205.48 | $54.84 |
Enterprise Value | $27.56B | $33.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
